Literature DB >> 28160825

[Glioblastoma in 2017].

Hugues Duffau1.   

Abstract

Glioblastomas are serious tumours of the central nervous system. Recurrence is systematic and prognosis poor. Radiotherapy and chemotherapy follow surgery, when surgery is possible, to lengthen survival, while preserving quality of life as much as possible. In this respect, symptomatic treatments and supportive care are necessary.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  biopsie; biopsy; chemotherapy; chimiothérapie; excision; exérèse; glioblastoma; glioblastome; radiotherapy; radiothérapie; soins de support; supportive care

Mesh：

Year:  2017        PMID： 28160825     DOI： 10.1016/j.revinf.2016.12.002

Source DB:  PubMed          Journal:  Rev Infirm        ISSN： 1293-8505


  4 in total

1.  AdipoR2 inhibits human glioblastoma cell growth through the AMPK/mTOR pathway.

Authors:  Chen Jie; Wang Xuan; Han-Dong Feng; Ding-Mao Hua; Wang Bo; Sun Fei; Zhang Hao
Journal:  Eur J Med Res       Date:  2021-03-22       Impact factor: 2.175

Review 2.  Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Lakshmi Thangavelu; Aleksey Dorofeev; Favian Bayas-Morejón; Naghmeh Shirafkan; Navid Shomali; Max Stanley Chartrand; Mostafa Jarahian; Ghasem Vahedi; Rebar N Mohammed; Somayeh Shahrokh; Morteza Akbari; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-03-22       Impact factor: 6.832

Review 3.  The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.

Authors:  Vincenzo Mattei; Francesca Santilli; Stefano Martellucci; Simona Delle Monache; Jessica Fabrizi; Alessandro Colapietro; Adriano Angelucci; Claudio Festuccia
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

4.  Limited recurrence distance of glioblastoma under modern radiotherapy era.

Authors:  Ziwei Tu; Huifen Xiong; Yang Qiu; Guoqing Li; Li Wang; Shiyi Peng
Journal:  BMC Cancer       Date:  2021-06-22       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.